PANDX FOR All

PANDX
COMPANY PROFILE 2024

1
⽬录
CONTENTS
CONTENTS

·PART 01

Products
·PART 02

Integrated Solutions

·PART 03
Global Distribution Network
OUR VISION

Leader in the Precision Pathogen Detection Field with

NGS
To Become a New Pillar of mNGS and tNGS Solutions in South-East Asia

PANDX FOR All

PANDX FOR All

Pan-Infection Diagnostics via Metagenomics(mNGS)

PRODUCTS

Targeted NGS for Pathogenic Microorganisms(tNGS)

（Pan-Infection panel 、Central Nervous System infection panel、
MTB&NTM infection panel、Fungal Infection panel）

OncoDx Panel
（ For Colorectal Cancer and NSCLC：14 genes panel+MSI）
mNGS Technology for Infection Diagnosis

Metagenomic Next-generation Sequencing (mNGS) combines shotgun sequencing of

clinical specimen with advanced bioinformatics. It offers quick, highly sensitive and
accurate results in a high throughput manner, with minimum bias and requirement.

Metagenomics is the foundation of clinical high-throughput pathogen detection.

 ©
META-ID
Pan-Infection Diagnostics via Clinical Metagenomics
Based on mNGS technology, it targets the detection of difficult and
critical pathogens, immunocompromised patients, and newly infected
Detect ALL diseases.
Predict antibiotic Applicable to different
pathogens
tolerance or sensitivity types of samples
and26,270
covers discover NEW!
types of pathogens.
predicts bacterial drug sensitivity Sample types include: BALF, sputum,
Bacteria: 12,895 types;
phenotype for 8 common drug-resistant blood, CSF, tissue, etc.,
Viruses: 11,120 types;
bacteria and 35 commonly used clinical exclusive host removal technology to
Fungi: 1,582 types;
antibiotics. handle samples with high human
Parasites: 312 types;
The accuracy rate is over 95% through nucleic acid content.
Mycoplasma/Chlamydia: 184 types;
clinical specimen verification. Supported by
Actinomycetes: 177 types.
patents."
Determining Factors for Clinical Metagenomics

“Host Contamination”The most impactful factor for clinical metagenomics

• BALF on average contains up to ~106 host cells/ml

• Sputum up to ~107 host cells/ml
• Host background can vary 10,000 time or more within the same
type of samples

？
Low biomass Difficulty in cell
BALF and CSF, 100 random samples
？ lysis
• BALF host background medium > 106 host cells/ml
？
Sequencing depth Effective
？
“Intracellular Microbes”could easily be missed
data

Obligate intracellular
：
Facultative intracellular
： 、
Macrophage engulf and spread hematogenous disseminated tuberculosis NTM Cryptococcus 、
、
Local recruitment of macrophage forms granulomas: TB Aspergillus NTM 、
Selective Cell Lysis for High Host Contamination

PANDX dehost reagents can

improve the effective
sequencing reads as much
as 100 times

Mechanism
01 Human somatic cells have a single layer of
member, easy to break; Most pathogen
cells have thicker protections (such as cell
walls) as a survival strategy

Methods
02 Denaturant (break host cell membrane)+
Dnase or Other Chemicals (remove
released host DNAs ）
GenseqAMR Rapid Drug Susceptibility Prediction
Sector-only clinical drug resistance database with
Database highly accurate phenotype associations>90%
building
Genotype Whole genome Drug
Phenotype data susceptibility Strain-Feature-
data Patented ML
Associations Drug Susceptibility
>40,000 multi-source strains algorithm for drug
Ensure the validity of the resistance features （GenseqResDB）
associations
GenseqAMR

Drug resistance
gene detection

SMART drug
resistance gene Drug susceptibility
species algorithm report

Clinical Pathogen
Clinical
Specimen detection
Metagenomics
Pathogen
detection report

Ref:
1. Hu, et al. Novel Clinical mNGS-Based Machine Learning Model for Rapid Antimicrobial Susceptibility Testing of Acinetobacter baumannii. Journal of Clinical Microbiology
(2023)
2. Liu, et al. Direct prediction of carbapenem resistance in Pseudomonas aeruginosa by whole genome sequencing and metagenomic sequencing. Journal of Clinical
Microbiology (2023)
PANDX FOR All

Pan-Infection Diagnostics via Metagenomics(mNGS)

PRODUCTS

Targeted NGS for Pathogenic Microorganisms(tNGS)

（Pan-Infection panel 、Central Nervous System infection panel、
MTB&NTM infection panel、Fungal Infection panel）

OncoDx Panel
（ For Colorectal Cancer and NSCLC：14 genes panel+MSI）
Targeted NGS for Pathogenic
Microorganisms(tNGS)

Targeted Next-generation Sequencing (tNGS) combines multiplex PCR and NGS to identify
thousands of known pathogenic microorganisms and their associated virulence and/or drug
resistance genes in the specimens. The methods excels in its sensitivity, enabling the detection
of pathogens even at low concentrations in a cost-effective manner.
multi-
Library
Pretreatment Extraction targeted Sequencing
Preparation
amplification
Primer 1

Primer 2

：
Core Technical Difficulties
......
Ultra multi-targeted
Primer XX-1
Primer Design

Primer XX
Targeted NGS for Pathogenic Microorganisms

Pan-Infection panel Central Nervous System infection

panel

，
Detection of pathogens in general scenarios include Detect central nervous system infections, covers 163 pathogens,
238 pathogens, 15 types of drug resistance genes, inclue bacteria, fungi, viruses, mycoplasma, and parasites.
DNA+RNA pathogens co-detection. DNA+RNA pathogen co-detection.

MTB&NTM infection panel Fungal Infection

panel
Detect MTBC & 16 types of NTM, plus 4 types of first- Detect 77 types of fungi + 3 types of antifungal resistance
line anti-tuberculosis & 10 types of second-line drugs, genes, include yeast-like fungi, filamentous fungi,
47 pathogens of co-infections. dimorphic fungi and mycetoma pathogens.
tNGS: Pan-Infection Panel

78 Bacteria 30 Special Pathogens

238 pathogens,
24 DNA Viruses 46 Fungi
15 resistance genes

54 RNA Viruses
6 Parasites

■ Applications: Respiratory System Infections, Bloodstream Infections, Nervous System Infections, and Other Localized Infections
■ Population: Community-acquired Infections or Hospital-acquired Infections
■ Accpeted Sample Types: bronchoalveolar lavage fluid(BALF), sputum, blood, cerebrospinal fluid, tissue, and pleural/ascitic fluid, etc.
■ LOD≤100copies/ml
Pathogen List of Pan-Infection Panel-PART1
Category Pathogenic microorganisms
、 、 、 、
Staphylococcus aureus Streptococcus pneumoniae Streptococcus pyogenes Streptococcus agalactiae Streptococcus
、 、 、 、
dysgalactiae Streptococcus intermedius Streptococcus constellatus Enterococcus faecium Enterococcus
（ ） 、 、 、 、 、
faecalis Corynebacterium diphtheriae Nocardia farcinica Nocardia cyriacigeorgica Nocardia abscessus Nocardia
G+ n=28 、 、 、 、 、 、
asteroids Nocardia brasiliensis Listeria monocytogenes Listeria grayi Bacillus anthracis Bacillus cereus Enterococcus
、 、 、 、 、
faecium Enterococcus faecalis Tropheryma whipplei Rhodococcus equi Staphylococcus epidermidis Micrococcus
、 、 、 、 、
luteus Actinomyces israelii Actinomyces bovis Actinomyces naeslundii Actinomyces viscosus Schaalia odontolytica
Klebsiella pnenmoniae、Klebsiella oxytoca、Klebsiella aerogenes、Escherichia coli、Pseudomonas aeruginosa、Enterobacter
Bacteria cloacae complex、Stenotrophomonas maltophilia、Acinetobacter baumannii、Acinetobacter nosocomialis、Acinetobacter
pittii、Acinetobacter junii、Acinetobacter lwoffii、Haemophilus influenzae、Burkholderia cepacia、Burkholderia
（n=78 ） cenocepacia、Burkholderia pseudomallei、Burkholderia mallei、Moraxella catarrhalis、Elizabethkingia
meningoseptica、Elizabethkingia miricola、Elizabethkingia anophelis、Proteus mirabilis、Proteus vulgaris、Citrobacter
G- (n=50) freundii、Citrobacter koseri、Citrobacter braakii、Bordetella pertussis、Bordetella parapertussis、Bordetella
holmesii、Haemophilus parainfluenzae、Haemophilus haemolyticus、Brucella、Leptospira、Vibrio vulnificus、Vibrio cholerae
O1/O139、Salmonella typhi、Salmonella paratyphi、Legionella pneumophila、Bacteroides fragilis、Rothia
mucilaginosa、Fusobacterium nucleatum、Serratia marcescens、Achromobacter xylosoxidans、Neisseria meningitidis、Yersinia
pestis、Aeromonas hydrophila complex、Finegoldia magna、Veillonella parvula、Prevotella intermedia、Porphyromonas
gingivalis
Mycobacterium tuberculosis complex、Mycobacterium avium complex、Mycobacteroides abscessus、Mycobacteroides
massiliense、Mycobacteroides bolletii、Mycobacterium marinum、Mycobacterium kansasii、Mycobacterium
（
MTB&NTM n=17) xenopi、Mycobacteroides cheloei、Mycobacterium ulcerans、Mycolicibacterium fortuitum、Mycobacterium
scrofulaceum、Mycobacterium simiae、Mycobacterium gordonae、Mycobacterium haemophilum、Mycobacterium
vaccae、Mycobacterium malmoense
Mycoplasma pneumoniae、Mycoplasma hominis、Chlamydia psittaci、Chlamydia pneumoniae、Chlamydia
trachomatis、Ureaplasma urealyticum、Ureaplasma parvum、Coxiella burnetii、Orientia tsutsugamushi、Rickettsia
Specific
pathogens n=13（ ） typhi、Rickettsia prowazekii、Rickettsia rickettsii、Anaplasma phagocytophilum
Mucorales、Mucor、Rhizomucor、Lichtheimia、Rhizopus、Aspergillus、Cunninghamella、Candida albicans、Candida
tropicalis、Candida krusei、Candida parapsilosis complex、Candida auris、Candida glabrata、Candida lusitaniae、Trichosporon
asahii、Aspergillus fumigatus、Aspergillus flavus、Aspergillus niger、Aspergillus terreus、Pnuemocystis jiroveci、Cryptococcus
neoformans、Cryptococcus gattii、Histoplasma capsulatum、Talaromyces marneffei、Rhizopus oryzae、Rhizopus
（
Fungi n=46 ） microsporus、Rhizopus delemar、Rhizomucor pusillus、Lichtheimia corymbifera、Cunninghamella
bertholletiae、Scedosporium apiospermum、Fusarium fujikuroi、Fusarium moniliforme、Fusarium proliferatum、Fusarium
Pathogen List of Pan-Infection Panel-PART2
Category Pathogenic microorganisms

、 、 、
Macacine alphaherpesvirus 1 Human alphaherpesvirus 2 Human alphaherpesvirus 3 Human gammaherpesvirus 4 Human 、
、 、 、
betaherpesvirus 5 Human betaherpesvirus 6A Human betaherpesvirus 6B Human betaherpesvirus 7 Human 、
DNA virus （n=24） 、 、 、 、
gammaherpesvirus 8 Human adenovirus 6 Human adenovirus 3 Human adenovirus 7 Human adenovirus 14 Human 、
、 、 、 、
adenovirus 21 Human adenovirus 55 Human adenovirus 2 Human adenovirus 5 Human adenovirus E4 Primate 、
、 、 、 、
erythroparvovirus 1 Primate bocaparvovirus 1 Primate bocaparvovirus 2 Primate bocaparvovirus 3 Primate bocaparvovirus 4

、 、 、
Human respiratory syncytial virus A Human respiratory syncytial virus B Human metapneumovirus Influenza A virus
、 、 、 、 、
H1N1 Influenza A virus H3N2 Influenza A virus H5N1 Influenza A virus H7N9 Influenza B virus Influenza C virus Human 、
、 、 、 、
respirovirus 1 Human orthorubulavirus 2 Human respirovirus 3 Human orthorubulavirus 4 Human Coronavirus
、 、 、 、
229E Human Coronavirus HKU1 Human Coronavirus NL63 Human Coronavirus OC43 Severe acute respiratory syndrome
、 、
coronavirus 2 Severe acute respiratory syndrome-related coronavirus Middle East respiratory syndrome-related
RNA virus （n=54） 、 、 、 、 、 、
coronavirus Rhinovirus A Rhinovirus B Rhinovirus C Measles virus Rubella virus Mumps virus Human 、
、 、
parechovirus Sapporo virus Rotavirus 、、 、 、 、 、
Enterovirus A Enterovirus A71 Enterovirus B Enterovirus C Enterovirus
、 、 、 、 、 、 、
D Enterovirus D68 Echovirus E6 Echovirus E9 Echovirus E11 Echovirus E30 Coxsackievirus A2 Coxsackievirus
、 、 、 、 、 、
A6 Coxsackievirus A10 Coxsackievirus A16 Coxsackievirus B1 Coxsackievirus B2 Coxsackievirus B3 Coxsackievirus
、 、 、 、
B4 Coxsackievirus B5 Coxsackievirus B6 Bunya virus/Brazoran virus/Dabie bandavirus/SFTS phlebovirus Dengue
、 （ ）、
virus Hantaan virus Hantaan orthohantavirus 、
Yellow Fever Virus Crimean-Congo hemorrhagic fever orthonairovirus

Entamoeba histolytica、Paragonimus westermani、Toxoplasma gondii、Cryptosporidium tyzzeri、Pentatrichomonas

Parasite（n=6）
hominis、Leucocytozoon caulleryi

、 、 、 、 、 、 、
Drug resistance genes rpoB MP 23S rRNA KPC CTX-M mecA/C-MREJ NDM IMP VIM vanA 、vanB、OXA-23-like、OXA-24、OXA-48-like、OXA-51-
（ n=15 ） 、
like OXA-58
Pathogen List of Pan-Infection Panel-PART3
Type Category Resistance gene Associated species Drug
Monoamylin;Carbapenem;
KPC Klebsiella pnenmoniae
Cephalosporin;Penicillin
OXA-23 family
OXA-51 family
Cephalosporin;Penicillin
OXA-48 family Acinetobacter baumannii
OXA-24 family
carbapenem
OXA-58 family
Klebsiella pnenmoniae
Carbapenem;Cephalosporin;Penicillin;
Resistenc NDM ;Escherichia coli;Enterobacter
;Cephalomycin
e Genes cloacae;Pseudomonas aeruginosa
IMP Pseudomonas aeruginosa; Carbapenem;Cephalosporin;Penicillin;
VIM Klebsiella pnenmoniae ;Cephalomycin;Pencillene
Three
Klebsiella pnenmoniae;
generations of CTX-M Cephalosporin
Escherichia coli
cephalosporin

Methicillin 、
mecA/C sccmec_orfx Staphylococcus aureus
Monoamylin;Carbapenem;
Cephalosporin;Penicillin;Cephalomycin
Enterococcus faecium;
Vancomycin vanA/vanB Glycopeptide antibiotics
Enterococcus faecalis
Mycobacterium tuberculosis
Rifampicin rpoB Rifampicin
Resistanc complex
e MP 23S rRNA
mutations macrolide (2063/2064/2067/2617 Mycoplasma pneumoniae Macrolide antibiotic
Proven Clinical Scenarios of Pan-Infection
Panel

Tropical Diseases: A collective term for chronic infectious diseases that occur predominantly in tropical and subtropical regions
worldwide
parasitic infections such as malaria, schistosomiasis, ascariasis, leishmaniasis, hookworm disease, among others;
bacterial infections such as leprosy and cholera;
and viral infections such as dengue fever and yellow fever.
Produt scope includes:
• Newly-emerging Bunyavirus, Dengue Virus, Hantavirus, Yellow Fever Virus, Crimean-Congo Hemorrhagic Fever Virus
• Mycobacterium ulcerans, Chlamydia trachomatis, Vibrio cholerae O1/O139
• Entamoeba histolytica, Paragonimus westermani (lung fluke), Toxoplasma gondii, Human Cryptosporidium spp., Microsporidium spp.
• Histoplasma capsulatum, Blastomyces dermatitidis, Cryptococcus neoformans, Rhizopus microsporus, Rhizopus arrhizus, Rhizopus delemar, Rhizomucor
miehei, Phialophora parasitica, Cladosporium herbarum, Fusarium spp.., Scleroderma citrinum, Pseudallescheria boydii, Sporothrix schenckii, Talaromyces
marneffei (formerly Penicillium marneffei), and other pathogenic fungi such as Sporothrix brasiliensis, Coccidioides immitis, Coccidioides posadasii, and
Blastomycosis dermatitidis.

After the product upgrade,it will include:

• Leishmania donovani, infantile Leishmania species, Mycobacterium leprae, Plasmodium spp.,Taenia solium, Rabies virus
• Phialophora parasitica, Scedosporium aurantiacum, Scedosporium prolificans, Rhizopus microsporus, Rhizopus stolonifer, Mucor indicus, Curvularia lunata;
Aspergillus nidulans, Aspergillus lentulus, Aspergillus tubingensis, Aspergillus versicolor, Aspergillus carbonarius, Aspergillus clavatus, and Aspergillus
candidus.
tNGS: Central Nervous System Infection Panel

48 Bacteria 22 DNA Viruses 55 RNA Viruses

17 Special Pathogens 25 Fungi 11 Parasites

■ Applications: distinguishing autoimmune encephalitis from infectious encephalitis; pathogen identification in patients with suspected central nervous system infections.

■ Population: For patients with suspected central nervous system (CNS) infections where the etiology is unclear, empirical treatments have proven ineffective, and the

severity ranges from mild to moderate to severe, including those with immunodeficiency (suppression).

■ Acccepted Sample Types: Cerebrospinal fluid; when necessary, brain tissue biopsy samples or blood samples may also be collected and submitted for testing.

■ LOD≤111copies/ml
tNGS: MTB&NTM Infection Panel

7 resistance genes associated with 4 first-line anti-

tuberculosis drugs, 13 resistance genes associated
Mycobacterium tuberculosis with 10 second-line anti-tuberculosis drugs
complex
4 first-line anti-tuberculosis drugs

Rifampicin (rpob) 、 、
Isoniazid (katG inhA ahpC) Pyrazinamide(pncA) 、
Ethambutol(embB embA)

16 non-tuberculosis 10 second-line anti-tuberculosis drugs

mycobacteria 、 、
Streptomycin(rpsL rrs gid) 、
Fluoroquinolones(gyrA gyrB) Linezolid(rplC) 、
Ethionamide(inhA ethA)

47 pathogenic requiring differential 、

Protionamide(inhA ethA)
Sodium Aminosalicylate
、
(folC thyA)
Cycloserine(alr) Clofazimine(Rv0678)

diagnosis from tuberculosis or with

、 （ddn）
reported co-infections
Bedaquiline(Rv0678 atpE) Delamanid

■ Applications: Tuberculosis and drug resistance gene testing, differentiation diagnosis between tuberculosis and NTM (nontuberculous mycobacteria) infections.
■ Population: Patients suspected of having tuberculosis or NTM disease, patients with recurrent tuberculosis, and patients with tuberculosis considered to have multidrug
resistance.
■ Accepted Sample Types include bronchoalveolar lavage fluid(BALF), sputum, blood, cerebrospinal fluid, tissue, and pleural/ascitic fluid, etc.
■ LOD ：10-50copies/ml
tNGS: Fungal Infection Panel (Potential Star Product)

12 41
Yeast-like fungi Filamentous
fungi

8 1
Biphasic fungi Fugal podotoma causative agent

Aspergillus: cyp51A-mediated triazole resistance

Candida: fks-mediated resistance to Echinocandin
Pneumocystis yersoni: dhps-mediated resistance to trimethoprim/sulfamethoxazole
and atovaquone

■ Applications: Clinically suspected cases of fungal infections; Could serves as a secondary testing option within a universal panel.
■ Accepted Sample Types include bronchoalveolar lavage fluid(BALF), Sputum, pleural effusion, ascites, cerebrospinal fluid, peripheral blood, and tissue.
■ LOD≤100copies/ml
Coverage of WHO Priority List of Pathogenic Fungi

“WHO Priority List of Pathogenic Fungi: Guidance on research, development and public
health Behaviour” classifies 19 pathogenic fungi into three levels based on fatality rate,
，
infection rate and difficulty in diagnosis and treatment: Critical Priority Group High
，
Priority Group Medium Priority Group.

WHO fungal
priority
pathogens list to
guide research,
development and
public health
（
action 2022 ）
Pathogen List of Fungal Infection Panel l-PART1
Category Genus Representative strain

（ ） 、 、 、
Candida albicans Candida glabrata Candida tropicalis Candida parapsilosis complex 、Candida
Candida n=8
、 、 、
krusei Candida auris Candida lusitaniae Candida dubliniensis
Cryptococcus（n=2） 、
Yeast-like
fungi（n=14）
Cryptococcus neoformans Cryptococcus gattii
Pnuemocystis（n=1） Pnuemocystis jiroveci
Trichosporon（n=3） 、 、
Trichosporon asahii Trichosporon beigelii Trichosporon capitum
Aspergillus fumigatus、Aspergillus flavus、Aspergillus niger、Aspergillus terreus、Aspergillus
Aspergillus（n=6）
nidurans、Aspergillus candidus
Rhizomucor、Mucor、Rhizopus、Lichtheimia、Cunninghamella、Rhizopus
microsporus、Rhizopus oryzae、Rhizomucor pusillus、Rhizomucor pusillus、Cunninghamella
bertholletiae、Lichtheimia ramosa、Lichtheimia corymbifera、Rhizopus delemar、Mucor
Mucorales
（
(Order) n=17 ） irregularis、Mucor circinelloides、Mucor_indicus、Mucor_racemosus、Syncephalastrum
racemosum
（ ）
Acanthamoeba n=5 、
Curvularia Exophiala 、Scedosporium、Sporothrix、Cladosporium cladosporioides
Filamentous Talaromyces（n=1） Talaromyces marneffei
（
fungi n=51 ） 、 、
Fusarium solani species complex (FSSC) Fusarium oxysporum species complex(FOSC) Fusarium

（ ） 、 （ ）、
fujikuroi species complex(FFSC) Fusarium dimerum species complex FDSC Fusarium
Fusarium n=6
（ ）、
chlamydosporum species complex FCSC Fusarium incarnatum equiseti species
（
complex FIESC ）
（ ）
Scedosporium n=3 、 、
Scedosporium apiospermum Scedosporium aurantiacum Scedosporium boydii
Alternaria（n=2） 、
Alternaria alternata Alternaria infectoria
Paecilomyces（n=2） Paecilomyces variotii、Paecilomyces marquandii
Rasamsonia（n=1） Rasamsonia
Pathogen List of Fungal Infection Panel l-PART2
Category Genus Representative strain
（ ）
Schizophyllum n=1 Schizophyllum commune
Purpureocillium（n=1） Purpureocillium lilacinum

Filamentous Lomentospora（n=1） Lomentospora prolificans

（
fungi n=51） Microascus（n=2） 、
Microascus cinereum Microascus trigonosporus
Scopulariopsis（n=2） Scopulariopsis brevicaulis 、Scopulariopsis brumptii
Trichoderma（n=1） Trichoderma longibrachiatum
Coccidioides（n=2） 、
Coccidioides immitis Coccidioides posadasii
Paracoccidioides（n=1） Paracoccidioides brasiliensis

Biphasic Histoplasma（n=1） Histoplasma capsulatum

（ ）
fungus n=7 Sporothrix（n=1） Sporothrix schenckii
Blastomyces（n=1） Blastomyces dermatitidis
Geotrichum（n=1） Geotrichum candidum

（ ）
Others n=5
Fugal podotoma causative
（ ）
agent n=6
、 、 、
Madurella mycetomatis Fusarium Senegal Medicopsis romeroi Exophiala jeanselmei
Pathogen List of Fungal Infection Panel l-PART3

Number Category Pathogen Drug Gene Mutation sites

Resistant Aspergillus 、
TR34/L98H TR46/Y121F/
1
gene fumigatus
triazole (chemistry) cyp51A
、 、 、
T289A G54 G138 M220 G448 、
2
Resistant
gene
Candida triazole (chemistry) erg11 、 、 、 、
Y132H I471T T315A S405F R467K

3
Resistant
gene
Candida Echinocandins fks1 、 、
F641S S645P S629P

4
Resistant
gene
Candida Echinocandins fks2 S663P、 F659S/V/Y
Sulfamethoxazole/
5
Resistant
gene
Pnuemocystis
jiroveci
Methoxybenzylamino DPHS 、
T55A P57S
pyrimidine
 Targeted NGS for Pathogenic Microorganisms
（Pan-Infection panel 、Central Nervous System infection panel、
MTB&NTM infection panel、Fungal Infection panel）

■ Product Advantage Summary ：

Feature 1: Short TAT: Test to Report within 1 business day.

Feature 2: Comprehensive detection range: Respiratory system, Nervous system, Cardiovascular system infections

Feature 3: High detection sensitivity: the limit of detection (LOD) as low as 50 to 100 copies/mL.
PANDX FOR All

Pan-Infection Diagnostics via Metagenomics(mNGS)

PRODUCTS

Targeted NGS for Pathogenic Microorganisms(tNGS)

（Pan-Infection panel 、Central Nervous System infection panel、
MTB&NTM infection panel、Fungal Infection panel）

OncoDx Panel
（ For Colorectal Cancer and NSCLC：14 genes panel+MSI）
OncoDx Panel

• Actionable targets for Colorectal Cancer, Lung Cancer

Oncogenes Colorectal Cancer * Lung Cancer † FDA-APPROVED THERAPY

KRAS ✅ ✅ Cetuximab*
NRAS ✅ Panitumumab*
BRAF ✅ ✅ Dabrafenib + Trametinib†, Encorafenib*,

ERBB2 ✅ ✅ Tucatinib with Trastuzumab*, Ado-trastuzumab emtansine,

Pertuzumab
KIT √ Imatinib*
MSI ✅ Pembrolizumab*
NTRK1 ✅ ✅ Larotrectinib†
NTRK2 ✅ ✅ Larotrectinib†
NTRK3 ✅ ✅ Larotrectinib†
PIK3CA √

EGFR ✅ Afatinib†, Gefitinib†, Osimertinib †, Erlotinib†, Cetuximab,

Panitumumab

ALK ✅ Alectinib †, Brigatinib †, Crizotinib †, Ceritinib †, Lorlatinib †

ROS1 ✅ Crizotinib †, Entrectinib †

RET ✅ ✅ Selpercatinib †, Pralsetinib †
MET ✅ Lorlatinib†, Capmatinib †

✅ Genes Recommended by NCCN Guidelines

Actionable Targets

• Actionable Panel for Colorectal Cancer, Non-Small Cell Lung Cancer

Actionable OncoDx Panel Hybrid Capture-based Flexible sequencing

Enrichment platform

14
Actionable markers
from NCCN MSI
Guidelines
（Tissue sample）
10 markers

NCCN Guideline Recommendation:
◆ 9 genes and MSI for Colorectal Cancer;
◆ 11 genes for NSCLC;
DNBSEQ-E25
（CE-IVD ）
Hybrid Capture-Based Enrichment ◆ PE150, 7.5GB output
◆ Higher uniformity ◆ 5-10 samples per run
◆ Lower sequencing failures rates ◆ Flexible and Affordable

Panel Size: ~170K

◆ Easier customizations ◆ Easy to use

Depth: 2000X
Optimized Lab Process Workflow
• Market leading tissue-based capture approach that provide actionable benefits for cancer patients and oncologists
• All samples are processed through the following steps of validated workflow
• Turnaround time: 3-4 days

DNBSEQ-
E25
（ ）
CE-IVD
PE150,
7.5GB
 OncoDx Panel
（ For Colorectal panel+MSI
Cancer and NSCLC：14 genes
）

■ Product Advantage Summary ：

Feature 1: Accurate targeting NCCN-recommended testing genes for lung cancer and colorectal cancer.

Feature 2: Comprehensive coverage of currently approved targeted drugs on the market.

Feature 3: Low cost per test

What PANDX Can Supply: Reagents and Software Systems

mNGS Core Universal reagents for mNGS & Software

Reagent tNGS Systems

mNGS Library Preparation

Pretreatment / Extraction /
tNGS Core Sequencing
Reagent

tNGS Library Preparation tNGS Library Preparation tNGS Library Preparation tNGS Library Preparation
for Pan-infection Panel for Central Nervous for MTB&NTM Infection for Fungal Infection
System Infection Panel Panel Panel
PANDX FOR All

Integrated Solutions
Sequencing platforms can be diverse and compatible with illumina and MGI, etc.
PANDX FOR All

Sealing Oil

Amplification system

Bead Beating Automatic Nucleic Acid Intelligent Data

Library under the Oil Storsge DNBSEQ-E25
Grinder and Lysis
System
Extraction System
（ ）
CE-IVD （No.20202210158
Center
（ No.20210673 ） （ No. 20220570） ）

Grinder and Lysis Nucleic Acid Library Preparation Sequencing Analysis Report
20min Extraction 0.5h 3h 4h 0.5h

Extremely low Cost Quick and flexible Perfect throughput Compact and Easy to
Carry
You can acquire a Entire process takes ~8.5 E25 Sequencer 25 million Simple installation and
complete set of hours, enabling effortless reads throughput perfectly maintenance, no calibration when
equipment with no local delivery; Start-up suits multi-target moved; Disposable integrated
additional costs for time can be flexibly amplification for oncogenes, microfluidic assay card cartridge,
relocation or installation scheduled (ICL allows for pathogens, and NIPT no need for cleaning and reducing
postponed
Simple and start-up
user-friendly,
the E25 products,
sequencer enabling full-
perfectly suits
the risk of cross-contamination.
times). scenario applications.
the needs of overseas laboratories for conducting various assays.
PANDX FOR All
：
E25 is recommended You can acquire a complete set of equipment
with no additional costs for relocation or installation

DNBSEQ- tNGS
E25
（ ）
CE-IVD NIPT 40-50 tests
4-5 tests
Library
DNBSEQ-E25
（CE-IVD ）

OncoDx
5-10 tests

PANDX for ALL

Sequencing platforms can be diverse and compatible with illumina and MGI, etc.
PANDX FOR All

Global Distribution Network

PANDX FOR All

Beijing
R&D center and Clinical
Lab

Tianjin
GMP & Clinical Lab

Shanghai
Clinical Lab

Guangzhou
Clinical Lab

Vietnam·Ho Chi Minh

Joint Laboratory (Operational from April)
Thailand·Bangkok
Laboratory (Planning)

Indonesia·Jakarta
Joint Laboratory
Singapore Asia-pacific (Planning)
Regional Center
PanDx Already in operation
PANDX FOR All

37